National Health (Weighted average disclosed price – April 2026 reduction day) Determination 2025
PB 161 of 2025
made under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the
National Health Act 1953
Compilation No. 1
Compilation date: 5 March 2026
Includes amendments: F2026L00193
This compilation is in 3 volumes
Volume 1: sections 1-9
Volume 2: Schedule 1
Volume 3: Schedule 2
Endnotes
About this compilation
This compilation
This is a compilation of the National Health (Weighted average disclosed price – April 2026 reduction day) Determination 2025 that shows the text of the law as amended and in force on 5 March 2026 (the compilation date).
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au).
Application, saving and transitional provisions
If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Editorial changes
For more information about any editorial changes made in this compilation, see the endnotes.
Presentational changes
The Legislation Act 2003 provides for First Parliamentary Counsel to make presentational changes to a compilation. Presentational changes are applied to give a more consistent look and feel to legislation published on the Register, and enable the user to more easily navigate those documents.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. Any modifications affecting the law are accessible on the Register.
Self‑repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
Contents
1 Name
2 Commencement
3 Repeal
4 Authority
5 Definitions
Part 1 – Brands of pharmaceutical items with a weighted average disclosed price; adjusted approved ex-manufacturer price and reduction day
6 Weighted average disclosed price for brands of pharmaceutical items in Schedule 1
7 Adjusted approved ex-manufacturer price for brands of pharmaceutical items
8 Reduction Day
Part 2 – Brands of pharmaceutical items with a weighted average disclosed price
9 Weighted average disclosed price for brands of pharmaceutical items in Schedule 2
1 Name
(1) This instrument is the National Health (Weighted average disclosed price – April 2026 reduction day) Determination 2025.
(2) This instrument may also be cited as PB 161 of 2025.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | The day after this instrument is registered. | 20 December 2025 |
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Repeal
The National Health (Weighted average disclosed price – October 2025 reduction day) Determination 2025 (PB 71 of 2025) is repealed.
4 Authority
This instrument is made under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the National Health Act 1953.
5 Definitions
Note: A number of expressions used in this instrument are defined in section 99ADB of the Act, including the following:
(a) adjusted approved ex-manufacturer price;
(b) data collection period
(c) unadjusted price reduction;
(d) weighted average disclosed price.
In this instrument:
Act means the National Health Act 1953.
Part 1 – Brands of pharmaceutical items with a weighted average disclosed price; adjusted approved ex-manufacturer price and reduction day
6 Weighted average disclosed price for brands of pharmaceutical items in Schedule 1
(a) For subsection 99ADB(4) of the Act, the weighted average disclosed price of a brand of pharmaceutical item specified in column 2 of an item in the table to Schedule 1 is the amount specified in column 3 of that table item.
(b) Subsection (a) applies in respect of a data collection period for a brand of pharmaceutical item ending on 30 September 2025.
Note: Paragraph 99ADH(1)(a) of the Act applies if, under section 99ADB, the Minister determines the weighted average disclosed price of a brand of a pharmaceutical item in respect of a data collection period for the brand.
7 Adjusted approved ex-manufacturer price for brands of pharmaceutical items
The adjusted approved ex-manufacturer price of a brand of pharmaceutical item specified in column 2 of the table to Schedule 1 is the amount equal to the amount of the weighted average disclosed price of that brand of pharmaceutical item determined under section 6 of this instrument.
Note: Subsection 99ADB(7) of the Act provides that a determination made under subsection 99ADB(4) in relation to a brand of pharmaceutical item may include the adjusted approved ex-manufacturer price of the brand of pharmaceutical item.
8 Reduction Day
For paragraph 99ADH(1)(aa) of the Act, a brand of pharmaceutical item specified in column 2 of an item in the table to Schedule 1 has a reduction day of 1 April 2026.
Part 2 – Brands of pharmaceutical items with a weighted average disclosed price
9 Weighted average disclosed price for brands of pharmaceutical items in Schedule 2
(a) For subsection 99ADB(4) of the Act, the weighted average disclosed price of a brand of pharmaceutical item specified in column 2 of an item in the table to Schedule 2 is the amount specified in column 3 of that table item.
(b) Subsection (a) applies in respect of a data collection period for a brand of pharmaceutical item ending on 30 September 2025.
Note: This instrument does not determine a reduction day for paragraph 99ADH(1)(aa) of the Act for a brand